Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 12,944 Shares of Company Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $19.22, for a total value of $248,783.68. Following the sale, the chief executive officer directly owned 382,594 shares in the company, valued at $7,353,456.68. This trade represents a 3.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Omada Health Stock Performance

OMDA stock traded down $3.86 during trading on Friday, reaching $15.09. The company had a trading volume of 4,708,188 shares, compared to its average volume of 1,269,705. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $25.45. The company has a market cap of $923.76 million, a price-to-earnings ratio of 301.80 and a beta of 2.13. The firm has a 50-day simple moving average of $20.33 and a 200-day simple moving average of $17.74.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.02 by $0.08. The business had revenue of $91.31 million for the quarter. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. Sell-side analysts expect that Omada Health, Inc. will post 0.09 earnings per share for the current year.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
• Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
• Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action

Hedge Funds Weigh In On Omada Health

Several institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC increased its position in Omada Health by 1,161.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock valued at $33,000 after acquiring an additional 1,452 shares during the period. Versant Capital Management Inc lifted its stake in Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Omada Health during the 2nd quarter worth $53,000. State of Alaska Department of Revenue purchased a new position in Omada Health in the 3rd quarter worth about $59,000. Finally, Legal & General Group Plc purchased a new position in shares of Omada Health in the second quarter worth approximately $76,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Barclays reduced their target price on shares of Omada Health from $24.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday. Zacks Research cut shares of Omada Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. BMO Capital Markets reissued an “outperform” rating and set a $24.00 price target on shares of Omada Health in a research note on Friday, August 7th. Weiss Ratings cut Omada Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Omada Health in a research note on Friday, September 11th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Omada Health has an average rating of “Moderate Buy” and an average price target of $26.33.

About Omada Health

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.